ASCO

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Oncology

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.

Patients

ASCO 26: Three cancer survivors share lessons for the field

In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

News

ASCO26: Celcuity punished as trial disappoints investors

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

ASCO 26: Three cancer survivors share lessons for the field

ASCO 2026: Chinese firms take a front seat in oncology, with...

ASCO26: Celcuity punished as trial disappoints investors

ASCO26: In vivo CAR-Ts in the spotlight

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

ASCO

Editor's Picks